Security
ClearPoint Neuro, Inc. Common Stock · CLPT
CLPTNASDAQCommon stockCurrentCIK 1285550Updated Oct 29, 2026
Name history
MRI INTERVENTIONS, INC. · through Feb 11, 2020SURGIVISION INC · through Oct 22, 2010SURGI VISION INC · through May 2, 2007
CLPT price & chart
Loading TradingView…
NASDAQ:CLPT on TradingView ↗About the company
ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company uniquely provides both established clinical products as well as preclinical development services for controlled drug and device delivery. The Company’s flagship product, the ClearPoint Neuro Navigation System, has FDA clearance and is CE-marked. ClearPoint Neuro is engaged with healthcare and research centers in North America, Europe, Asia, and South America. The Company is also partnered with the most innovative pharmaceutical/biotech companies, academic centers, and contract research organizations, providing solutions for direct central nervous system delivery of therapeutics in preclinical studies and clinical trials worldwide. To date, thousands of procedures have been performed and supported by the Company’s field-based clinical specialist team, which offers support and services to our customers and partners worldwide. For more information, please visit www.clearpointneuro.com.
In the news
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT ↗
Seeking Alpha
ClearPoint Neuro outlines 5 IRRAflow milestones for 2027 as it prepares for potential AMT-130 approval timeline ↗
ClearPoint Neuro, Inc. (CLPT) Q3 2026 Earnings Call Transcript ↗
Cedar Grove Capital Q3: Adds Zedcor, Auxly; exits MTY, ClearPoint ↗
SEC disclosures
ClearPoint Neuro, Inc. files 8-K: Material Event ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
4 filing
SCHEDULE 13G/A - filed by MAK CAPITAL ONE LLC regarding ClearPoint Neuro, Inc.
10-Q filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 60,357,000Source | 40,193,000Source | 86,741,000Source | 62,869,000Source | 52,574,000Source | 93,416,000Source | 30,070,000Source | 53,637,000Source | 97,747,000Source | 39,189,000Source | 42,661,000Source | 55,490,000Source |
| Property, Plant and Equipment, NetUSD | 2,114,000Source | 1,695,000Source | 2,986,000Source | 2,019,000Source | 1,545,000Source | 2,914,000Source | 2,183,000Source | 1,347,000Source | 2,621,000Source | 2,005,000Source | 1,389,000Source | 806,000Source |
| GoodwillUSD | — | — | 7,472,000Source | — | — | 7,472,000Source | — | — | 7,472,000Source | — | — | — |
| Intangible Assets, Net (Excluding Goodwill)USD | — | — | 12,915,000Source | — | — | 13,419,000Source | — | — | 13,922,000Source | — | — | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 38,221,000Source | 21,573,000Source | 29,363,000Source | 41,541,000Source | 32,845,000Source | 35,593,000Source | 12,387,000Source | 35,353,000Source | 45,923,000Source | 20,104,000Source | 23,140,000Source | 27,615,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 4,000,000Source | 3,875,000Source | 8,395,000Source | 4,260,000Source | 3,475,000Source | 8,662,000Source | 3,651,000Source | 2,511,000Source | 6,549,000Source | 4,713,000Source | 3,211,000Source | 2,665,000Source |
| Inventory, NetUSD | 6,583,000Source | 7,059,000Source | 8,813,000Source | 6,293,000Source | 8,031,000Source | 8,573,000Source | 6,582,000Source | 7,960,000Source | 8,359,000Source | 6,863,000Source | 7,911,000Source | 9,303,000Source |
| Assets, CurrentUSD | 51,329,000Source | 34,330,000Source | 48,932,000Source | 53,991,000Source | 46,556,000Source | 54,877,000Source | 24,214,000Source | 47,570,000Source | 63,600,000Source | 33,363,000Source | 36,172,000Source | 51,180,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,525,000Source | 1,823,000Source | 2,361,000Source | 1,897,000Source | 2,205,000Source | 2,049,000Source | 1,594,000Source | 1,746,000Source | 2,769,000Source | 1,683,000Source | 1,910,000Source | 1,723,000Source |
| Operating Lease, Right-of-Use AssetUSD | 5,955,000Source | 3,210,000Source | 12,644,000Source | 6,139,000Source | 3,330,000Source | 13,088,000Source | 2,960,000Source | 3,447,000Source | 8,430,000Source | 3,086,000Source | 3,564,000Source | 1,895,000Source |
| Other Assets, NoncurrentUSD | 959,000Source | 148,000Source | 1,792,000Source | 720,000Source | 149,000Source | 1,646,000Source | 148,000Source | 149,000Source | 1,702,000Source | 148,000Source | 109,000Source | 131,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 44,483,000Source | 11,192,000Source | 75,965,000Source | 43,126,000Source | 20,442,000Source | 74,575,000Source | 10,083,000Source | 19,053,000Source | 69,727,000Source | 13,800,000Source | 21,488,000Source | 18,603,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 284,000Source | 276,000Source | 305,000Source | 284,000Source | 276,000Source | 300,000Source | 280,000Source | 274,000Source | 294,000Source | 276,000Source | 247,000Source | 246,000Source |
| Retained Earnings (Accumulated Deficit)USD | -209,124,000Source | -185,984,000Source | -237,799,000Source | -203,233,000Source | -181,010,000Source | -226,462,000Source | -197,396,000Source | -176,602,000Source | -216,910,000Source | -191,370,000Source | -172,456,000Source | -150,367,000Source |
| Stockholders' Equity Attributable to ParentUSD | 15,874,000Source | 29,001,000Source | 10,776,000Source | 19,743,000Source | 32,132,000Source | 18,841,000Source | 19,987,000Source | 34,584,000Source | 28,020,000Source | 25,389,000Source | 21,173,000Source | 36,887,000Source |
| Additional Paid in Capital, Common StockUSD | 224,714,000Source | 214,709,000Source | 245,703,000Source | 222,692,000Source | 212,866,000Source | 239,468,000Source | 217,103,000Source | 210,912,000Source | 238,995,000Source | 216,483,000Source | 193,382,000Source | 187,008,000Source |
| Liabilities and EquityUSD | 60,357,000Source | 40,193,000Source | 86,741,000Source | 62,869,000Source | 52,574,000Source | 93,416,000Source | 30,070,000Source | 53,637,000Source | 97,747,000Source | 39,189,000Source | 42,661,000Source | 55,490,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 8,053,000Source | 7,554,000Source | 10,313,000Source | 7,398,000Source | 16,694,000Source | 9,480,000Source | 6,866,000Source | 15,157,000Source | 10,765,000Source | 10,353,000Source | 7,430,000Source | 6,788,000Source |
| Operating Lease, Liability, CurrentUSD | 347,000Source | 536,000Source | 194,000Source | 331,000Source | 516,000Source | 234,000Source | 578,000Source | 497,000Source | 694,000Source | 557,000Source | 424,000Source | 561,000Source |
| Accounts Payable, CurrentUSD | 723,000Source | 955,000Source | 2,153,000Source | 1,531,000Source | 822,000Source | 2,330,000Source | 1,216,000Source | 844,000Source | 1,256,000Source | 1,340,000Source | 393,000Source | 272,000Source |
| Operating Lease, Liability, NoncurrentUSD | 6,195,000Source | 3,158,000Source | 13,520,000Source | 6,280,000Source | 3,302,000Source | 13,710,000Source | 2,860,000Source | 3,438,000Source | 8,461,000Source | 3,011,000Source | 3,568,000Source | 1,532,000Source |
| Deferred Income Tax Liabilities, NetUSD | — | — | 321,000Source | — | — | 354,000Source | — | — | 354,000Source | — | — | — |
| Other Liabilities, NoncurrentUSD | 263,000Source | — | 1,068,000Source | — | — | 779,000Source | — | — | 489,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Deferred Revenue, CurrentUSD | — | 1,252,000Source | — | — | 1,079,000Source | — | — | 1,232,000Source | — | 2,121,000Source | 2,613,000Source | 1,066,000Source |
| Deferred Revenue, NoncurrentUSD | — | 480,000Source | — | — | 446,000Source | — | — | 458,000Source | — | 436,000Source | 541,000Source | 390,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 354,000Source | 0Source | 38,000Source | 39,000Source |
| Long-term DebtUSD | 29,203,000Source | — | 50,232,000Source | 28,845,000Source | 9,979,000Source | 49,644,000Source | — | 9,964,000Source | 49,077,000Source | — | 9,949,000Source | 9,893,000Source |
| Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 9,874,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 86,000Source | 103,000Source | 814,000Source | 980,000Source | 626,000Source | 244,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,218,000Source | 1,908,000Source | 8,180,000Source | 6,907,000Source | 6,079,000Source | 4,126,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 2,019,000Source | -846,000Source | 268,000Source | 1,206,000Source | 1,804,000Source | 211,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 125,000Source | -78,000Source | 103,000Source | -743,000Source | -1,246,000Source | 4,421,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -7,967,000Source | -6,172,000Source | -23,925,000Source | -8,950,000Source | -13,720,000Source | -16,167,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -645,000Source | -183,000Source | 615,000Source | -275,000Source | 8,949,000Source | -10,736,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 645,000Source | 183,000Source | 522,000Source | 275,000Source | 717,000Source | 253,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 1,993,000Source | 1,305,000Source | 1,856,000Source | 424,000Source | 210,000Source | 336,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -1,845,000Source | -1,362,000Source | 50,179,000Source | 6,189,000Source | 296,000Source | 409,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -10,457,000Source | -7,717,000Source | 26,869,000Source | -3,036,000Source | -4,475,000Source | -26,494,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 38,401,000Source | 21,573,000Source | 30,288,000Source | 41,721,000Source | 36,516,000Source | 12,387,000Source | 46,973,000Source | 20,104,000Source | 23,140,000Source | 27,615,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 525,000Source | 0Source | 908,000Source | 480,000Source | 743,000Source | 523,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 2,022,000Source | 1,904,000Source | 2,271,000Source | 2,269,000Source | 2,218,000Source | 1,908,000Source | 8,180,000Source | 6,907,000Source | 6,079,000Source | 4,126,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | 42,000Source | 0Source | 83,000Source | 51,000Source | 57,000Source | 55,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | 503,000Source | 0Source | 504,000Source | 0Source | 168,000Source | — | — | — |
| DepreciationUSD | — | — | — | — | — | — | — | — | 400,000Source | — | — | — |
| Depreciation, Amortization and Accretion, NetUSD | — | — | — | — | — | — | 523,000Source | 231,000Source | 1,255,000Source | 923,000Source | 831,000Source | 533,000Source |
| GoodwillUSD | — | — | — | — | 7,472,000Source | — | 7,472,000Source | — | 7,472,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | 8,000Source | 14,000Source | -38,000Source | 25,000Source | 8,000Source | 18,000Source | 55,000Source | 12,000Source | 8,000Source | 0Source |
| InterestExpenseNonoperatingUSD | — | — | — | — | 1,413,000Source | 365,000Source | 1,382,000Source | 0Source | 2,388,000Source | — | — | — |
| Investment Income, InterestUSD | — | — | — | — | 289,000Source | 285,000Source | 351,000Source | 151,000Source | 1,213,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -5,891,000Source | -4,974,000Source | -11,337,000Source | -5,837,000Source | -9,552,000Source | -6,026,000Source | -25,540,000Source | -18,914,000Source | -22,089,000Source | -16,435,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -64,000Source | -11,000Source | -7,000Source | -52,000Source | -35,000Source | 4,000Source | -146,000Source | -40,000Source | -29,000Source | -22,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 0Source | 3,263,000Source | 16,149,000Source | — | 0Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 148,000Source | 21,000Source | 127,000Source | 21,000Source | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 8,861,000Source | 8,122,000Source | 10,880,000Source | 9,215,000Source | 12,128,000Source | 8,485,000Source | 36,971,000Source | 31,390,000Source | 23,955,000Source | 20,551,000Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Selling, General and Administrative ExpenseUSD | — | — | 3,586,000Source | 3,141,000Source | 5,554,000Source | 3,388,000Source | 4,997,000Source | 4,082,000Source | 16,498,000Source | 11,998,000Source | 11,756,000Source | 9,611,000Source |
| Operating Income (Loss)USD | — | — | -5,276,000Source | -5,158,000Source | -10,244,000Source | -5,680,000Source | -8,478,000Source | -6,163,000Source | -24,164,000Source | -19,746,000Source | -22,446,000Source | -16,332,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -64,000Source | -11,000Source | -7,000Source | -52,000Source | -35,000Source | 4,000Source | -146,000Source | -40,000Source | -29,000Source | -22,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -5,883,000Source | -4,960,000Source | -11,375,000Source | -5,812,000Source | -9,544,000Source | -6,008,000Source | -25,485,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | 8,000Source | 14,000Source | -38,000Source | 25,000Source | 8,000Source | 18,000Source | 55,000Source | 12,000Source | 8,000Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -5,891,000Source | -4,974,000Source | -11,337,000Source | -5,837,000Source | -9,552,000Source | -6,026,000Source | -25,540,000Source | -18,914,000Source | -22,089,000Source | -16,435,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.21Source | -0.18Source | -0.38Source | -0.21Source | -0.32Source | -0.22Source | -0.9Source | -0.7Source | -0.9Source | -0.68Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.21Source | -0.18Source | -0.38Source | -0.21Source | -0.32Source | -0.22Source | -0.9Source | -0.7Source | -0.9Source | -0.68Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 28,427,574Source | 27,591,623Source | 30,166,640Source | 28,258,305Source | 29,546,889Source | 27,718,918Source | 28,315,254Source | 27,027,692Source | 24,605,212Source | 24,181,854Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 28,427,574Source | 27,591,623Source | 30,166,640Source | 28,258,305Source | 29,546,889Source | 27,718,918Source | 28,315,254Source | 27,027,692Source | 24,605,212Source | 24,181,854Source |
| Interest Expense (non-operating)USD | — | — | — | — | 1,413,000Source | 365,000Source | 1,382,000Source | 0Source | 2,388,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | 503,000Source | 0Source | 504,000Source | 0Source | 168,000Source | — | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | — | — | — | 200,000Source | 200,000Source | 100,000Source |
| Gross ProfitUSD | — | — | 5,600,000Source | 4,847,000Source | 6,710,000Source | 5,556,000Source | 7,756,000Source | 5,132,000Source | 22,692,000Source | 19,122,000Source | 13,614,000Source | 13,531,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 81,000Source |
| Interest Income (Expense), NetUSD | — | — | -543,000Source | 209,000Source | — | -80,000Source | — | 151,000Source | — | 872,000Source | 386,000Source | — |
| Investment Income, InterestUSD | — | — | — | — | 289,000Source | 285,000Source | 351,000Source | 151,000Source | 1,213,000Source | — | — | — |
| Research and Development ExpenseUSD | — | — | 3,452,000Source | 3,315,000Source | 4,632,000Source | 3,829,000Source | 4,522,000Source | 3,379,000Source | 13,897,000Source | 12,392,000Source | 11,709,000Source | 10,894,000Source |
| Selling and Marketing ExpenseUSD | — | — | 3,838,000Source | 3,549,000Source | 6,768,000Source | 4,019,000Source | 6,715,000Source | 3,834,000Source | 16,461,000Source | 14,478,000Source | 12,595,000Source | 9,358,000Source |
Offerings
Registration 333-292733
Filing attachments
clpt-ex99_1.htm · 8-K · 2026-10-28
Exhibit 99.1 ClearPoint Neuro Reports Third Quarter 2026 Results Neurosurgery Navigation & Therapy Grew 59% to $5.4 Million SOLANA BEACH, CA, October 28, 2026 - ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its third quarter ended September 30, 2026. Third Quarter 2026 Highlights • Reported third quarter revenue of $12.1 million, represe…
Read attachment ↗clpt-ex99_2.htm · 8-K · 2026-10-28
WHEN YOUR PATH IS UNCLEAR, WE POINT THE WAY. Nasdaq: CLPT October 2026 1 © 2026 CLEARPOINT NEURO DISCLAIMER FORWARD-LOOKING STATEMENTS Statements in this presentation and discussion concerning ClearPoint Neuro’s (the “Company’s”) plans, growth, and strategies may include forward-looking statements within the meaning of the federal securities laws. Statements regarding the Company’s future events, developments and future performance; the continued development, anticipated timing, and potential c…
Read attachment ↗clpt-ex99_1.htm · 8-K · 2026-08-03
EX-99.1 2 clpt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ClearPoint Neuro Reports Second Quarter 2026 Results Positive BioPharma Partner Regulatory Progress and Early Success in Focused Ultrasound Technology Platform Expansion SOLANA BEACH, CA, August 3, 2026 - ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its second quarter ended June …
Read attachment ↗clpt-ex99_2.htm · 8-K · 2026-08-03
EX-99.2 3 clpt-ex99_2.htm EX-99.2 WHEN YOUR PATH IS UNCLEAR, WE POINT THE WAY. Nasdaq: CLPT August 2026 1 © 2026 CLEARPOINT NEURO DISCLAIMER FORWARD-LOOKING STATEMENTS Statements in this presentation and discussion concerning ClearPoint Neuro’s (the “Company’s”) plans, growth, and strategies may include forward-looking statements within the meaning of the federal securities laws. Statements regarding the Company’s future events, developments and future performance; the continued development…
Read attachment ↗clpt-ex99_1.htm · 8-K · 2026-05-13
EX-99.1 2 clpt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ClearPoint Neuro Reports First Quarter 2026 Results Record Revenue Achieved Including 25% Organic Growth in Devices and 43% Overall Growth SOLANA BEACH, CA, May 13, 2026 - ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its first quarter ended March 31, 2026. First Quarter 2026 Hig…
Read attachment ↗clpt-ex99_2.htm · 8-K · 2026-05-13
EX-99.2 3 clpt-ex99_2.htm EX-99.2 WHEN YOUR PATH IS UNCLEAR, WE POINT THE WAY. Nasdaq: CLPT May 2026 1 © 2026 CLEARPOINT NEURO DISCLAIMER Statements in this presentation and discussion concerning ClearPoint Neuro’s (the “Company’s”) plans, growth, and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance; the continued development, anticipated timing, and pote…
Read attachment ↗